Search
Search Results
##search.searchResults.foundPlural##
-
IRON DEFICIENCY ANAEMIA AMONG PRE-SCHOOL CHILDREN WITH SICKLE CELL ANAEMIA: STILL A RARE DIAGNOSIS?
1516PDF: 875HTML: 2958cover leer: 188 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1703PDF: 1127HTML: 492 -
BONE MARROW ABONRMALITIES IN HIV INFECTION
2006PDF: 1200HTML: 1783 -
-
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3840PDF: 963HTML: 6884 -
MENDELIAN SUSCEPTIBILITY TO MYCOBACTERIAL DISEASE IN EGYPTIAN CHILDREN
3514PDF: 917HTML: 1170Cover: 230 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1655HTML: 689PDF: 907 -
Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY GENE THERAPY FOR HEMOPHILIA
2279PDF: 2007HTML: 529 -
JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia
3389PDF: 663Suppl. Files: 321HTML: 289 -
COULD PLASMA GLUCOSE (PG) INCREMENT (PG %) EXPAND THE CLINICAL WEIGHT OF OGTT? PRELIMINARY FINDINGS IN 19 TDT PATIENTS (Β-TDT) WITH NORMAL GLUCOSE TOLERANCE Plasma glucose (PG) increment (PG %) and pancretic β-cell dysfunction in thalassemia
826PDF: 700HTML: 136 -
EFFICACY AND SAFETY OF SINOPHARM VACCINE FOR SARS-COV-2 AND BREAKTHROUGH INFECTIONS IN IRANIAN PATIENTS WITH HEMOGLOBINOPATHIES: A PRELIMINARY REPORT Sinopharm Vaccination in Iranian Patients with Hemoglobinopathies
1819PDF: 787HTML: 247 -
ACQUIRED REFRACTORY IRON DEFICIENCY
3742PDF: 1284HTML: 1554 -
THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA in TDT
226PDF: 257HTML: 58 -
A MULTICENTER ICET-A STUDY ON AGE AT MENARCHE AND MENSTRUAL CYCLES IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA (TDT) WHO STARTED EARLY CHELATION THERAPY WITH DIFFERENT CHELATING AGENTS. Age at menarche and menstrual cycles in patients with transfusion-dependent thalassemia.
888PDF: 598HTML: 188 -
MANAGEMENT OF PORTAL VEIN THROMBOSIS IN CIRRHOTIC PATIENTS
861PDF: 579HTML: 4040 -
Toxic epidermal necrolysis associated with severe cytomegalovirus infection in a patient on regular hemodialysis.
1847PDF: 601HTML: 17000Figure 4: 210Figure 3: 178Figure 2: 182Figure 1: 217 -
THE ROLE OF WHITE BLOOD CELL COUNT IN PERIANAL PATHOLOGIES: A RETROSPECTIVE ANALYSIS OF HEMATOLOGIC MALIGNANCIES Role of white blood cell count in perianal pathologies
4202PDF: 2048HTML: 282 -
An unusual cause of anemia and encephalopathy
4172PDF: 919HTML: 1548 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2391PDF: 1876HTML: 977 -
IS HEMOGLOBIN E GENE WIDELY SPREAD IN THE STATE OF MADHYA PRADESH IN CENTRAL INDIA? EVIDENCE FROM FIVE TYPICAL FAMILIES
2664PDF: 936HTML: 7999Untitled: 225 -
CURRENT ISSUES AND OPTIONS FOR HORMONAL CONTRACEPTION IN ADOLESCENTS AND YOUNG ADULT WOMEN WITH SICKLE CELL DISEASE: AN UPDATE FOR HEALTH CARE PROFESSIONALS Hormonal Contraception in Adolescents and Young Adult Women With Sickle Cell Disease
2321PDF: 1509HTML: 994 -
LIVER IRON CONTENT IN INDIVIDUALS WITH LIVER IRON CONTENT IN INDIVIDUALS WITH Β-THALASSEMIA TRAIT AND HYPERFERRITINEMIA: ROLE OF METABOLIC ALTERATIONS, HFE GENOTYPES, AND CIRRHOSIS.: ROLE OF METABOLIC ALTERATIONS, HFE GENOTYPES, AND CIRRHOSIS. Β-THALASSEMIA TRAIT AND HYPERFERRITINEMIA
299PDF: 331Suppl. Files: 41HTML: 123 -
POST-LOAD PLASMA GLUCOSE INCREASE (PG-GAP) AS A RISK FACTOR FOR DEVELOPING DYSGLYCEMIA IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (Β-TDT): RETROSPECTIVE ANALYSIS OVER 8 YEARS Post load plasma glucose increase and the risk of glucose dysregulation in thalassemia
615PDF: 292HTML: 174 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1850PDF: 1250HTML: 356 -
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
3845PDF: 1362HTML: 2174Fig.1: 257Fig. 2: 247







